Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BiondVax Pharmaceuticals Ltd. BVXV
$1.79
-$0.02 (-1.11%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
5976989.00000000
-
week52high
14.10
-
week52low
1.70
-
Revenue
0
-
P/E TTM
-7
-
Beta
2.46608900
-
EPS
-3.92000000
-
Last Dividend
0.00000000
-
Next Earnings Date
13 мая 2021 г. в 20:00
Описание компании
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Aegis Capital | Buy | 26 янв 2022 г. | |
| Aegis Capital | Buy | 26 июн 2015 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
BiondVax to Present at BIO-Europe Spring
GlobeNewsWire
16 мар 2023 г. в 13:10
JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.
BiondVax Presenting at BIO CEO & Investor Conference
GlobeNewsWire
02 февр 2023 г. в 14:15
JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference . The conference is taking place Feb. 6-9, 2023, in New York.
Best Penny Stocks To Buy? 5 To Watch After Big News This Week
PennyStocks
23 янв 2023 г. в 09:28
Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?
BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
PRNewsWire
21 ноя 2022 г. в 06:00
JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference.
BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference
PRNewsWire
03 ноя 2022 г. в 11:30
JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer , BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place November 6 to 9, 2022 in Orlando, Florida.